False Medicare Part D Event Data: When the Data Disagrees With the Prescription

Whistleblower Justice Network

Medicare Part D false prescription drug event data misrepresents the prescriber, the prescription or the costs behind a plan’s federal payment. A pharmacy employee sees the prescription. A pharmacy benefit manager’s analyst sees the value sent to the Centers for Medicare & Medicaid Services. A finance employee sees the reconciliation. The useful question is where those accounts diverge, who understood the difference, and what happened to the payment after someone raised it.

A prescriber field can pass a computer’s check while naming the wrong doctor. The HHS Office of Inspector General found that discrepancy by comparing event data with prescriptions held at pharmacies. When false data inflates the federal payment, taxpayers pay for the difference.

What Does a Prescription Drug Event Record?

A prescription drug event is the summary a Part D sponsor submits to CMS for a filled prescription. The agency’s description of prescription drug event data distinguishes that summary from the individual pharmacy transaction. Both stand-alone prescription drug plans and Medicare Advantage prescription drug plans submit these records.

The pharmacy sends a claim to the sponsor or its pharmacy benefit manager. The system accepts or rejects it, and an accepted claim leads to dispensing and pharmacy reimbursement. The sponsor then submits the CMS-facing event record, often through a pharmacy benefit manager acting on its behalf.

The event ties together the beneficiary, prescriber, dispensing pharmacy, drug, prescription reference, fill number, service date and payment information. Days supply and the prescriber identifier can be compared with the original prescription. Those details let an analyst connect a reported event to a particular fill rather than merely to a pharmacy’s total billing.

The sponsor certifies the accuracy, completeness and truthfulness of claims data submitted for payment. Contracting out claims processing leaves the sponsor responsible for its contract with the agency. For an insider, that puts the pharmacy’s information, the administrator’s processing and the sponsor’s certification in the same picture.

False Cost Data and Federal Payment

Prescription drug event records feed the calculations that reconcile federal payments to Part D sponsors. The Centers for Medicare & Medicaid Services pays sponsors prospectively, then compares those payments with the amounts supported by the year’s costs and payment data. Reinsurance, low-income cost sharing and other subsidy components have their own inputs.

False cost data enters that calculation through the reported payment fields. CMS’s reporting instructions for contract year 2026 separate the drug’s cost from what the patient, plan and subsidy programs pay. Manufacturer discounts also have their own field.

In one of the agency’s examples, a $320 selected-drug purchase carries a $32 selected drug subsidy, a $10 beneficiary copay and $278 reported as covered plan paid. The same prescription already has several payment figures before annual reconciliation.

Rebates and other price concessions also affect the sponsor’s net costs through direct and indirect remuneration reporting, usually called DIR. Understating those concessions overstates net drug costs. The prescription drug event, the DIR report and the reconciliation each supply part of the federal payment calculation. To establish the money at issue, we connect the challenged event to the applicable calculation and the resulting payment or adjustment. A field’s treatment, the benefit design and the date of the prescription have to travel together.

False Fill Numbers, Days Supply and Prescription Origin

False prescription drug event data reaches beyond the prescriber’s identity. Fill numbers, days supply and prescription origin codes also tell the government what happened at the pharmacy.

In its October 2012 audit of Humana’s Schedule II drug events, the HHS Office of Inspector General examined a reporting system through which pharmacies had been paid approximately $438 million for those drugs. In 29 of 64 judgmentally selected event records, fields did not match pharmacy documentation.

The discrepancies were concrete. Fill numbers differed from the fills documented at the pharmacy. Days supply differed from the prescription. Prescription origin codes misidentified whether the order was written, telephoned, electronic or faxed. The audit also found wrong prescriber identifiers.

The Inspector General separately examined partial fills within that selection. Of 53 records reviewed, 16 represented unallowable partial fills, including 13 for drugs dispensed without a practitioner’s written prescription.

Humana’s third-party administrator, Argus Health Systems, processed pharmacy claims and created prescription drug event records. Humana submitted them to the Centers for Medicare & Medicaid Services. The Inspector General found that the administrator’s edits did not adequately ensure accurate fields or catch the unallowable partial fills.

We see the absurdity in that gap: the system processed the data while the pharmacy held the document that contradicted it. The check passed. The prescription said otherwise.

False Prescriber Identifier in PDE Data

A false prescriber identifier in PDE data is exposed when the submitted identifier does not match the prescriber on the pharmacy’s prescription. The Humana audit made that comparison directly.

In its 2022 audit of ineligible-provider data, the Inspector General described Part D requirements for sponsors and pharmacy benefit managers to reject pharmacy claims without active, valid provider identification numbers. It also found that the agency’s system edits did not identify all ineligible providers after sponsors submitted their data. An accepted record still needs to be traced back to the prescriber and prescription it describes.

Historical Part D Dummy Identifiers and Materiality

Historical Part D dummy identifiers raised a materiality question: did the inaccurate field matter to the government’s payment decision? CVS Caremark programmed default identifiers into records when actual prescriber identifiers were missing or incorrectly formatted, allowing those records through submission checks.

A former pharmacist who co-founded a pharmacy auditing company brought the whistleblower case. In its November 2017 decision, the Third Circuit ruled for Caremark because the identifiers did not matter to payment for the prescriptions at issue from 2006 and 2007. CMS knew of the practice and continued paying during that period.

CMS knowledge of Part D data defects is one reason we examine agency communications alongside internal decisions. A dated notice, the agency’s response and the instructions employees received help us connect the disputed field to what the business knew when it certified the data.

Accepted, Rejected, Adjusted and Deleted Events

The correction history shows which version of a prescription drug event reached the payment calculation. Submitted, accepted and rejected records, later adjustments and deletions, certifications and reconciliation reports belong together when examining false event data.

A pharmacy’s corrected record and the sponsor’s CMS submission may sit in different systems. We compare the source prescription with the original event and its later versions, then connect those versions to the sponsor’s payment records. The point is to find what changed, when it changed, and whether the change reached the calculation that used the data.

The Centers for Medicare & Medicaid Services’ attestation instructions for 2025 reconciliation data, issued in 2026, required an executive signature and addressed retroactive adjustments. They also allowed a specified attachment for a potential or identified prescription drug event error already reported to the agency. That gives an insider a concrete comparison: the error discussion, the correction trail and the certification signed afterward.

Part D overpayments bring the payment consequence into focus. Whether the sponsor is entitled to keep the money depends on the applicable reconciliation. We trace the event correction through that reconciliation and any subsequent return of funds, so the concern rests on what the sponsor submitted and retained.

The Records Behind the Pattern

The most useful Medicare fraud evidence connects the prescription, the transmitted value, the warning and the money. Pharmacy staff can explain the prescription and fill information. Plan and pharmacy benefit manager employees can explain the data processing and submissions. Finance staff can connect those submissions to certifications and reconciliation.

An internal warning can show who knew about a recurring discrepancy. A software ticket can identify the change described as a fix. Subsequent records can show whether the same problem continued. These are the connections we examine with someone who understands the healthcare business and its systems.

A 2018 study in the Journal of Big Data, Big Data fraud detection using multiple medicare data sources, combined Part B, Part D and durable medical equipment data to look for fraud patterns. The study used the National Provider Identifier to connect records to a provider before the data mining began. That is where an insider adds something a model cannot supply: an explanation of why the submitted identifier differs from the original prescription. We connect that explanation to the decisions and payment records behind it.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. We assess the evidence and the potential whistleblower reward together, with the specific Part D submission and payment at the center of the case.

When You Know Why the Data Changed

If you work for a plan, PBM or pharmacy and know why prescriber, fill or cost data was changed or left uncorrected, speak with our whistleblower experts about the events behind it. We work with you to build the case from the prescription through the federal payment and bring in Medicare Part D whistleblower lawyers who understand sponsor reporting and pharmacy systems. We stay with you through the whole journey to build your strongest Part D whistleblower case.

WHISTLEBLOWER JUSTICE NETWORK CAN HELP YOU
Make a difference.
Whistleblower Justice NetworkReport Fraud
100% CONFIDENTIALFREE CONSULTATION24 / 7 / 365